ClinicalTrials.gg
Enrolling by invitationNCT05492799Updated Aug 9, 2023

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

A Phase 4 interventional study of AX 250 in MPS III B, sponsored by Allievex Corporation. Enrolling by invitation at 6 sites in 5 countries. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Allievex Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Planned enrollment
13th of 23
15 · median 17
Started
2022
with 1 other
Phase 4
Only one
of the 43
Primary completion
2027-10
later than 7 of 14 live
Registered
33rd of 43
by date
Lead sponsor
5 of 43
Allievex Corporation

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 4, reaches primary completion later than 7 of the 14 other live ones, and was the 33rd registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3B/4, multicenter, multinational, open label study to further evaluate intracerebroventricular (ICV) delivered AX 250 treatment in MPS IIIB subjects that complete Study 250-202 for up to an additional 3 years (144 weeks) of treatment with AX 250 administered by ICV infusion every other week. Subjects will be evaluated for neurocognitive function, communication, adaptive behavior, quality of life, imaging characteristics and biochemical markers of disease burden. Safety will be assessed by adverse events, clinical labs, and physical exams.

03

Conditions studied

  • MPS III B
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have completed 240 weeks of Study 250-202 and enter 250-401 within 8 weeks of dosing completion.
  2. Provides written from parent or legal guardian and assent from subject, if required
  3. Has the ability to comply with protocol requirements in the opinion of the investigator
  4. If female with , must have a negative pregnancy test at the Screening visit and be willing to have additional pregnancy tests during the study

Exclusion criteria

Exclusion Criteria:

  1. Has (1) a cognitive age equivalent (AEq ) score ≤ 18 months, (2) a development quotient (DQ) score ≤ 20, and (3) no evidence of improvement during the 250-202 study in secondary or exploratory efficacy endpoints
  2. Would not benefit from enrolling in the study in the opinion of the investigator
  3. Has received stem cell, gene therapy or enzyme replacement therapy (other than AX 250) for MPS IIIB
  4. Has a history of poorly controlled seizure disorder
  5. Is prone to complications from ICV drug administration including patients with hydrocephalus or ventricular shunts
  6. Has received any medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
  7. Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    single arm

    AX 250 300 mg - open label

    Drug: AX 250

Interventions

  • DrugAX 250

    biweekly infusion by intracerebroventricular (ICV) infusion

06

What researchers measure

Primary outcomes

  1. Primary - neurocognition

    the rate of change in score from neurocognitive assessment using validated scale

    Time frame: baseline to 144 weeks of treatment

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Oct 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2022
First posted
Aug 9, 2022
StartActual
Dec 2, 2022
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05492799
Lead sponsor
Allievex Corporation
Responsible party
Sponsor
First posted
Aug 9, 2022
Start date
Dec 2, 2022
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 9, 2023

Study contacts

Medical Director
study director · Allievex Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tralesinidase alfa

Start the discussion